Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

285.45 -5.98 (-2.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 678,671
Open 288.70
Bid (Size) 285.46 (3)
Ask (Size) 291.00 (3)
Prev. Close 291.43
Today's Range 285.21 - 291.43
52wk Range 187.16 - 311.88
Shares Outstanding 147,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
2 Top Biotech Stocks Defying the Bear Market
These stocks soared in the double digits last year. 
Via The Motley Fool
Why Anavex Life Sciences Stock Bolted Higher in January
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results. 
Via The Motley Fool

Performance

YTD
+4.70%
+4.70%
1 Month
+3.91%
+3.91%
3 Month
+1.11%
+1.11%
6 Month
+29.14%
+29.14%
1 Year
+28.36%
+28.36%

More News

Read More
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'
Via Benzinga
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
Is Biogen Stock a Buy Now?
Via The Motley Fool
Where Biogen Stands With Analysts
Via Benzinga
FDA Rejects Eli Lilly's Donanemab For Alzheimer's Disease, Needs More Data
Via Benzinga
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Biogen Inc.
Via Globe NewsWire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Via Investor's Business Daily
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
Via InvestorPlace
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
Via InvestorPlace
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Via MarketBeat
Exposures Product Safety
Lecanemab Receives Priority Review Status in Japan
From Biogen Inc.
Via Globe NewsWire
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
From Biogen Inc.
Via Globe NewsWire
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
Via The Motley Fool
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
Via Investor's Business Daily
Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss
Via Benzinga
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
Via The Motley Fool
If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today
Via The Motley Fool
Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen
Via Benzinga
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
Via The Motley Fool
Elliott Wave Technical Analysis: Biogen Inc.
Via Talk Markets
1 Hot Growth Stock to Buy Now, and 1 to Avoid
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.